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Abstract: Nowadays, the freeze-drying of liposome dispersions is still necessary to provide a solid
dosage form intended for different routes of administration (i.e., parenteral, oral, nasal and/or
pulmonary). However, after decades of studies the optimization of process conditions remains
still challenging since the freezing and the dehydration destabilize the vesicle organization with
the concomitant drug leakage. Starting from the thermal properties of phospholipids, this work
reviews the main formulation and process parameters which can guarantee a product with suitable
characteristics and increase the efficiency of the manufacturing process. In particular, an overview of
the cryo- and/or lyo-protective mechanisms of several excipients and the possible use of co-solvent
mixtures is provided. Attention is also focused on the imaging methods recently proposed to
characterize the appearance of freeze-dried products and liposome dispersions upon reconstitution.
The combination of such data would allow a better knowledge of the factors causing inter-vials
variability in the attempt to improve the quality of the final medicinal product.
Keywords: cake appearance; cryoprotectant; freeze-drying; freezing rate; time and temperature;
liposomes; lyoprotectant; QbD; solvent; stability; sublimation
1. Introduction
Over the past decades, liposomes have evolved from models for artificial cells due to their
structural similarity to biological membranes, to very attractive drug delivery systems. Their use in
the pharmaceutical field is in large part due to good biocompatibility [1] and the ability to encapsulate
both hydrophilic and hydrophobic drugs in the aqueous core and in the bilayer, respectively [2].
The possible limitations in the development of liposomal dosage forms are usually related to
phenomena of oxidation and/or hydrolysis of lipids, drug leakage, the formation of aggregates or
vesicle fusion, with consequent alteration of the in vivo biodistribution and, therefore, efficacy and
safety [1–3]. When formulative approaches (i.e., use of saturated and/or high transition phase lipids,
addition of antioxidant agents, design of charged and functionalized particles, etc.) or precautionary
storage conditions (conservation in inert atmosphere, at−20 ◦C, protected from light) are not sufficient,
the only option to overcome these instability issues is to dry the liposome-based formulations, since all
the above mentioned phenomena are facilitated in an aqueous environment. Whenever liposomes are
intended to be administered by oral and/or pulmonary routes, the drying of the colloidal suspension
is unavoidable [4,5]. Among the possible approaches, lyophilization still remains the main studied
technique even if examples of marketed lyophilized drug products are very limited [6]. This is due
to the complexity of the process since the choice of excipients and process parameters to protect the
membrane integrity from stresses due to freezing and dehydration is challenging. In fact, liposomes
contain water and spontaneously assemble in the presence of water, then its removal may cause
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a significant, sometimes irreversible, alteration of their structure as clearly stated by Chen and
co-workers [7].
This work aims to review the literature not only on the formulation and process parameters,
which have been demonstrated to stabilize liposomal suspensions, but also on the methods suitable for
the characterization of freeze-dried and reconstituted liposome formulations. Moreover, considering
that the lyophilization is defined as a highly specialized process known to be complex [8] and that
liposomes are considered among the complex formulations [9,10], attention is also given to the quality
by design approach and to the related controls.
2. Thermotropic Behavior of Phospholipid Bilayers
Hydrated phospholipid membranes change between different phases, characterized by different
positions (i.e., lateral order) and orientation (i.e., rotational order). The two extreme phases of bilayer’s
phospholipids are the so-called gel and fluid phases [11]. The gel phase, also known as solid-ordered
phase, is characterized by the formation of a very compact bilayer with a minimum mobility since
hydrocarbon chains display an all-trans configuration favoring their maximum elongation (Figure 1).
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Figure 1. Thermotropic behavior of phospholipid bilayer in an aqueous medium. Tp: pre-transition
temperature, Tm: phase transition temperature.
Above a certain temperature, called phase transition temperature (Tm), the lipid bilayer undergoes
a gel–liquid transition: the lipid chains change onfiguration (fr m all-trans to all-gauche) and assume
a less extended and compact s ructure. Depending on the chemical struc ur (i.e., le gth and saturation
degree of the acyl chains, nature of the pol r heads, type and io ic force of the dispersion medium)
different lipids can have dramatically different Tm (Table 1).
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Table 1. Phase pre-transition (Tp) and transition (Tm) temperatures of fully hydrated phospholipids.
Phospholipids Acyl Chains Tm (◦C) Tp (◦C) Ref.
DLPC 12:0/12:0 −1 - [12,13]
DMPC 14:0/14:0 24 22.0 [13]
DPPC 16:0/16:0 40.5 35.5 [14]
DSPC 18:0 49.1 54.5 [13]
DOPC 18:1 −18 9.0 [13]
HSPC 16:0/18:0 53.6 47.8 [15]
EPC Mixed chains −15 to −20 - [13]
1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC); 1,2-dimyristoyl-sn-glycero-3-phosphocholine
(DMPC); 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC); 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); hydrogenated soy
phosphocholine (HSEP); egg phosphocholine (EPC).
In particular, the length and degree of unsaturation of the acyl chains have the most prominent
effect [13,16]. The longer the length of the acyl chains (or the lower the degree of unsaturation),
the higher the Tm of the phospholipid (Table 1). In some cases, the transition from gel to liquid phase
is preceded by a gradual change in the distance among polar heads (pre-transition, Tp) occurring a
few degrees before Tm (~5–7 ◦C). Above the Tp value a simultaneous variation in the phospholipid
configuration and membrane curvature occurs so that the bilayer surface is characterized by periodic
one-dimensional undulations, called the ripple phase (Figure 1). It is assumed that ripples are caused
by the alternation of gel and liquid lipid domains in a single monolayer: as different domains have
different geometrical characteristics, lipids are forced to arrange on the surface [17]. The difference
between Tp and Tm depends again on the length of hydrocarbon chains: the longer the length, the lower
the difference, up to the complete overlap for acyl chains having 22 carbon atoms [17,18]. Also in the
case of mixed chains (i.e., egg phosphocholine (EPC)) with a prevalence of C18 component, Tp moves
towards Tm and this, along with the presence of different metaphases, does not allow to discriminate
the two Tm values (Table 1). On the other hand, it is reported that saturated acyl chains ranging
between C10 and C13 do not pass through the ripple phase, but they undergo a direct gel-liquid
transition (Table 1) [13].
In addition, depending on the hydration level, hydrocarbon chains can be tilted or not tilted;
the angle of tilt increases with the increase of water content, obtaining a thin bilayer [19]. Other factors,
such as the type of phospholipid polar head or the presence of cholesterol, may influence the
chain tilt [20]. Cholesterol is one of the main components of liposomal formulation along with
phospholipids, since it regulates the fluidity of the bilayer and stabilize the membrane. As a matter
of fact, the hydrophobic steroidal moiety of cholesterol (and other similar substances) promotes the
all-trans configuration of acyl chains decreasing the tilt angle in gel phase. Moreover, the incorporation
of cholesterol in the bilayers causes a broadening, or elimination, of the Tm because it exerts an ordering
effect on the liquid phase that assumes physical characteristics in common with the solid-ordered gel
phase. In fact, the bilayer configuration in presence of cholesterol is defined liquid-ordered phase [21].
Differential scanning calorimetry (DSC) and microcalorimetry analyses are often used to study
the response of the lipid membrane to formulation additives and/or external factors, being either
a drug or an environmental stress. Nevertheless, these techniques can be applied only on very
simplified formulations, since for example the presence of cholesterol significantly decreases the
enthalpy variation associated Tm and, at high concentrations, hinders the transition [22]. Furthermore,
lipids with Tm values close to the fusion of ice have to be generally replaced by other lipids (mainly
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), Table 1) to observe the thermic events in a
proper manner [23]. A typical DSC pattern of lipid vesicle aqueous dispersion is represented in
Figure 2. An alternative technique is the fluorescence spectroscopy that can permit the measurement
of the dependence of the membrane fluidity on the variation of temperature also in presence of
cholesterol [24]. Furthermore, small-angle X-ray scattering (SAXS) or electron spin resonance [25],
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along with ellipsometric techniques [26] and Raman spectroscopy [24], can provide useful information
on the structural changes of the bilayers over a broad range of conditions.
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(DSC) in a simplified system: (A) typical trace of an amorphous protectant; (B) typical pattern of
liposomes made of a phospholipid with a Tm significantly higher than melting ice temperature;
(C) representation of an ideal thermogram registered on a liposome dispersion containing the protectant.
Tg’: glass transition temperature of maximum freeze concentrate; Tp: pre-transition temperature of
fully hydrated phospholipids; Tm: phase transition temperature of fully hydrated phospholipids.
3. Stresses of Liposomal Dispersions Occurring During Freeze-Drying
A typical freeze-drying process consists of three main phases: freezing, primary rying and
secondary drying. The freezing phase is a cooling step where most of the solvent is separated from the
liposomes and excipients, resulting in the formation of ice crystals. The annealing of a frozen sample
can be also introduced to decrease the sample heterogeneity and reduce the drying rate mainly due to
the increase of ice crystal size. The primary drying is initiated when the chamber pressure is reduced
to a few millibars and the shelf temperature is increased to supply heat required for sublimation.
During the secondary drying, temperature is raised to allow the water desorption. All these steps may
be critical for the liposome integrity and the retention of the entrapped compounds.
3.1. Freezing Step
The freezing ste can induce many dest bilizing stress fa tors because Tm is related to the
hydration state of phospholipids, and liposomal dispersions can account for different types of water
pools; bulk water and intraliposomal solution freeze at approximately −20 ◦C (heterogeneous ice
nucleation) and −45 ◦C (homogeneous ice nucleation), respectively [27,28].
At high hydrations and above freezing temperatures, lipid–water suspensions separate into
two different phases: a lamellar phase with about 30 water molecules per lipid and a bulk phase of
nearly pure water [29]. Decreasing the temperature, the bulk water starts to freeze and liposomes
approach to each other closely. Then, the lam llar phase begins to dehydrate de reasing the spacing
between the phosph lipid head groups. These e nts lead to a lateral expansion of the bilayer
resulting in a compressive stress in their plane. The possible consequences depend on the bilayer
composition and include demixing of more than one component in vesicles, micelle formation and
aggregation [29]. Moreover, the freezing determines a cryoconcentration of the solutes (i.e., excipients)
in the bulk solution, creating an osmotic gradient which causes a loss of the internal solution with
consequent leakage of dissolved hydrophilic drugs [30]. As an example, the addition of 10% of lactose
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to 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)/cholesterol liposomes caused the reduction
of internal volume and simultaneous invagination of the bilayer and self-fusion events which lead
to peanut-shaped liposomes (Figure 3) [31]. The osmotic shock is described to be independent of the
liposome size [32].
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Figure 3. Cryo-transmission electron microphotographs of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC)/cholesterol (60:40, mol/mol) liposomes prepared in water (a) and after addition of 10% (w/v)
lactose to the external solution (b). The microphotograph shown in (c) was collected after freezing the
liposome dispersion shown in (b). The black arrows denote peanut shapes structures, white arrows
collapsed outer membrane of double liposomes and arrowhead in the inset of (b) denotes a completely
collapsed liposome. Bars 1⁄4 100 nm. Reproduced with permission from [31], Elsevier Inc., 2010.
Freezing rate also has a significant impact on the maintenance of liposome structure. Ultrafast
cooling (e.g., immersion of small volume suspensions in liquid nitrogen) results in the formation of fine
ice crystals and a homogeneous distribution of the protectant, which might reduce the disruption of
the liposomal bilayer structure. On the other hand, a slow freezing rate reduces the supercooling [27]
and the osmotic pressure since water molecules can diffuse slowly across the bilayer when the external
solution becomes freeze-concentrated [33]. Consequently, a slow freezing rate (lower than 0.5 K/min)
may minimize the formation of ice crystals in the inner aqueous compartment and prevent drug
leakage [33]. Moreover, it was also hypothesized that slow freezing (1) provides more time to recover
from deformations produced by osmotic pressure and mechanical forces; (2) reduces the vesicles
located at the glass-ice boundary favoring their distribution in the glass matrix; and (3) reduces the
stress vectors affecting the rigid bilayers. In general, the effect of the freezing rate strongly depends on
the rigidity of the bilayer, or in other words, on lipid composition and presence of cholesterol. As an
example, DPPC liposomes are more stable than EPC ones during freezing (Table 1). Furthermore,
liposomes containing cholesterol in the bilayer are less damaged from a quick cooling because of the
increased order of the fluid phase in the presence of cholesterol [34].
The annealing of a frozen liposomal dispersion, known to improve the cake appearance, caused
the drug leakage of a water soluble-encapsulated drug probably because the bilayer underwent a
phase change [35]. Alternatively, two isothermal steps at 5 and −5 ◦C [36,37] can be added to reduce
the intrinsic stochasticity in this step.
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3.2. Drying Steps
The possible detrimental effects of drying steps mainly emerge during the rehydration of
the product [33]. As a matter of fact, the spatially separation of phospholipids is exerted by the
water molecules bound to the polar heads of lipids. The dehydration of phospholipids favors the
hydrophobic interactions between the acyl chains increasing the packing density of the bilayer [38].
As a result, the bilayer moves from a hexagonal phase, in which the lipid head groups surround
channels of water, to a ribbon phase in which lipid bilayers are packed to form a two-dimensional
lattice [39]. The increased order of the bilayer, demonstrated also by the decrease of the tilt of the
hydrocarbon backbone following dehydration, causes a drastic increase of the Tm (up to 60 ◦C) [38,40].
This increment seems to be strictly dependent on the nature of the polar heads of lipids, or, in other
words, on the type and the entity of the interactions occurring between polar heads and water
molecules and/or between adjacent polar heads. As an example, the strong intermolecular interactions
occurring between the ammonium and phosphate groups in phosphatidylethanolamines causes a
drastic increase of Tm after dehydration (from 63 to 100 ◦C) [40]. Thus, the stabilization of liposomal
structure relies on the maintenance of the Tm at the values of the fully hydrated bilayers to avoid a
gel–liquid transition during reconstitution since the rehydration of phospholipids is associated to
drug leakage. This goal may be obtained pre-heating the sample in the dry phase above the Tm or
using excipients interacting with the polar regions of liposomes able to maintain the liquid crystalline
state [41]. It should be mentioned that cholesterol itself may have a protective effect on the drying of
liposomes. In fact, as stated above, cholesterol causes a decrease in the Tm reducing the interactions
among the acyl chains. Moreover, it may interact with the polar heads of lipids through H-bond
formation due to the exhibition of the −OH group on the interfacial region. Indeed, some authors
hypothesized a possible competition between cholesterol and protectant excipients in the interaction
with lipid polar heads [42]. As a matter of fact, it was observed that the drug leakage upon rehydration
is lower in the presence of cholesterol [35].
From a process point of view, the primary drying can be considered a fine balance between mass
and heat transfer since the rate of the mass transfer is proportional to the latent heat of sublimation
of ice per unit mass. Moreover, the energy absorbed during sublimation must be compensated by a
supply of energy from another source, e.g., shelf, to avoid a dramatic reduction of the drying rate.
To define the process parameters of this stage, it is essential to determine the maximum allowable
product temperature. In the case of liposomal formulations, this temperature is usually related to the
glass transition temperature of maximum freeze concentrate (Tg’). This is a unique value, where the
residual non-ice phase forms a glass. In another words, the maximally freeze concentrated solution
becomes glass below Tg’ reaching viscosity values to the order of 1013–14 P; whereas increasing the
temperature above Tg’ results in an increase in mobility and the system changes to rubbery or liquid
phase. This transition can occur over a broad temperature range [43].
Tg’ values are considered predictive of the collapse temperature (Tc), namely the temperature at
which the frozen product can no longer support its structure and structural modifications, e.g., holes
or fissures, may be observed. If the sample temperature rises above Tc during the primary drying,
the cake can collapse (Figure 4A) with the concomitant vesicle fusion and/or aggregation [44,45].
Thus, a true measure of Tc is desirable to avoid a time (and energy) consuming process. To this
end, light transmission freeze-drying microscopy (FDM) is usually used. Alternatively, a new type
of freeze-drying microscope based upon time-domain optical coherence tomography (OCT-FDM),
recently proposed to design a lyophilization process [46,47], can be also used since it was able to detect
formulation at low solid content, as in the case of most of the freeze-dried liposomal formulations.
The secondary drying, or desorption step, determines the residual moisture content in the
final freeze-dried product and, therefore, its long-term stability and the quality of the reconstituted
pharmaceutical dosage form. The water content which cannot be removed by sublimation (Wg’) can be
considered the most significant factor determining the operative conditions of this step. As a matter
of fact, Wg’ is the content of plasticizing water in a glass matrix and, since the greater the Wg’ the
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lower the glass transition (Tg) value of dried product, it determines the long-term stability of the
product [48]. This feature also implies that not only the process, but all factors causing a variation of
moisture content during storage, e.g., stoppers [49], should be carefully evaluated.
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cake: total collapse (left) and partial collapse (center). The vial on the right shows no evidence of
collapse; (B) SEM images of freeze-dried liposomes in presence of trehalose (S:L = 5:1) with a 200 times
magnification (a); in presence of sucrose (S:L = 5:1) with a 250 times magnification (b); in presence
of sucrose nd m nnitol (S:L = 5:1) with a 250 times magnification; no lyoprotectant (c ntrol) with
a 200 times magnification (d); in presence of trehalose (S:L = 3:1) with a 200 times magnification,
(e) respectively. S:L repre ents the carbohydrate to lipid molar atio. The insert in red highlights the
crystallized mannitol in sample (c). Reproduced with permission from [50,51], Elsevier Inc., 2018.
Moreover, the secondary drying can cause overheating when the heating ramp or the holding time
are not carefully investigated. Only recently, the use of Raman and near-infrared (NIR) spectroscopy
was proposed as a com lementary tool of Pirani measur ments to supply the information about the acyl
chain packing of the liposo e bilay rs and pre ict if any ha mful ev nts would occur. This approach
would allow, giving a better understanding of the process, to improve process efficiency by optimizing
the primary and secondary drying time [50].
4. Stabilization by Excipients
Excipients with different biophysical and chemical properties, namely the protectants,
are included in outer aqueous phase of liposomal dispersions to stabilize the liposome membrane
during freeze-drying and reduce the detrimental effects, namely alterations of physical features of
vesicles and/or drug leakage, caused by the dehydration of phospholipids and cryo-concentration.
Generally speaking, amorph us protectants are preferred to crystalline substances which can damage
phospholi id bilayer du ing fre zing [52].
Sugars, and particularly disaccharides, are considered excipients of choice, although after
decades of studies on liposomes the protection mechanism is not fully understood. In 1973,
Crowe et al. proposed the water replacement hypothesis: the interactions, namely H-bonds, between
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the carbohydrates and phospholipid head groups replace those with water, stabilizing the vesicle
structure [53]. Later, it was demonstrated that sugars can bridge three phospholipids simultaneously
through multiple H-bonds [54]. More specifically, these excipients can simultaneously link through
H-bond to the carbonyl and phosphate groups of the polar heads and/or to the methyl group of
the hydrophobic moiety. Nevertheless, the phosphate group is the favorite for the interactions [55].
Fourier transform infrared (FTIR) spectroscopy supported the formation of these interactions since the
bands attributed to phosphate, carbonyl and ammonium moieties shifted toward other frequencies
after the freeze-drying cycle [53].
This behavior explains why the bilayer Tm decreases when a disaccharide is added.
Sugars increase the distance between phospholipid polar heads, minimizing van del Waals interactions
among hydrocarbon chains (Figure 5). As a result, sugars not only limit the Tm increasing during
dehydration, but they can also decrease Tm in completely hydrated bilayers (as schematized in
Figure 2). The interaction seems maximized for a sugar:lipid mass ratio of 5:1 [56], even if in the case
of disaccharides a beneficial effect occurred also at lower ratios (Table 2). As an example, when sucrose
was added to paclitaxel loaded pegylated liposomes, the paclitaxel retention was guaranteed already
at a sucrose concentration of 150 mM (sugar:lipid ratio 3:1 w/w) but in preventing the aggregation
assuring the presence of a monodisperse population after lyophilization, the maximum protectant
effect was observed at 5:1 sugar: lipid ratio (Table 2) [56]. Instead, in the case of monosaccharides,
such as glucose, a higher ratio (at least 9:1) may be required to have enough compound interacting
with the polar heads of lipids [57]. The concomitant encapsulation of a protectant in the aqueous core
of the vesicles can be beneficial because it abolishes, or at least reduces, the osmotic gradient caused by
cryoconcentration, preserving the size. Accordingly, it was demonstrated that the stabilization effect of
disaccharides is optimized by adding the excipient both inside and outside of liposomes with a 2:5
internal to external ratio [56].
The protective effect of sugars can be further explained considering the vitrification model.
According to this theory, upon freezing sugars form an amorphous phase with high viscosity and low
mobility that acts as a barrier between adjacent bilayers. This glassy matrix limits the fusion of vesicles
and protects the bilayer from damages caused by ice formation [58]. In other words, sugar molecules in
the bulk solution permit to maintain the distance among vesicles. As a result, sugars avoid the increase
of Tm and the leakage of hydrophilic compounds induced by the detrimental effect of extra-liposomal
ice (see above). To corroborate the implication of the vitrification theory in the protection of liposomes
by sugars, it was assumed that the surface tension of vesicles decreases because of the formation of
interactions among the liposome surface and the glassy matrix [59].
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Table 2. Overview of the main excipients tested as protectants of liposomes upon freeze-drying. To allow a quick comparison of the data, it was arbitrarily assumed
that the reconstitution is acceptable (Y) when a monodisperse population was obtained upon re-hydration and the hydrodynamic diameter of the resuspended
liposomes was lower than 3 times with respect to the value of the not freeze-dried formulation. Leakage was considered avoided (effective) if the retention of the
entrapped substance after freeze-drying was at least 90% of the original value.
Protectant Liposome Components
Effect
Ref.Reconstitution
(Protectant:lipids Ratio)
Avoiding Leakage
(Substance)
Mannitol POPC or DSPC: ls-PG: DSPE-PEG2000 Y (5-10:1 w/w) - [23]
Glucose
POPC or DSPC: ls-PG: DSPE-PEG2000
DOPC or DPPC or EPC
EPC
Y (5-10:1 w/w)
-
N ( (0-500 mg/mL)
-
Ineffective (calcein)
Ineffective in the range (CF)
[23]
[60]
[61]
Lactose
POPC or DSPC: ls-PG: DSPE-PEG2000 Y (5-10:1 w/w) - [23]
DPPC:DPPG:CHOL Y (5% w/w in; 15% out) Effective (doxorubicin) [48]
SPC or SPC:SPS or SPC:SPS:CHOL Y (5% w/w) - [52]
Maltose
DOPC or EPC
DPPC
-
-
Ineffective (calcein)
Effective (calcein) [60]
DPPC - Effective ( > 5:1 mol/mol) [62]
DPPC:DPPG:CHOL Y (5% w/w in; 15% out) Effective (doxorubicin) [48]
Sucrose
DPPC:DPPG:CHOL Y (5% w/w in; 15% out) Effective (doxorubicin) [48]
DOTAP:DOPE
DOTAP:DOPE:DSPE-PEG
Y (57:1 w/w)
Y (51:1 w/w)
-
- [63]
EPC Y (0-500 mg/mL) ≥50 mg/mL (CF) [61]
SPC:CHOL:DOTAP
EPC:CHOL:DOTAP
HSPC:CHOL:DOTAP
Y (3-15:1 w/w)
Y (3-15:1 w/w)
Y (20-25:1 w/w)
Ineffective (ATP)
Ineffective (ATP)
Not tested
[64]
DPPC:CHOL:DSPE-PEG Y (6:1 w/w) Ineffective (prednisolone) [65]
DOTAP:CHOL Y (1.6-2.7:1 w/w) Ineffective (decapeptide) [66]
SPC
SPC:SPS
SPC:SPS:CHOL
Y (5% w/w)
Y (5% w/w)
Y (5% w/w)
-
-
-
[52]
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Table 2. Cont.
Protectant Liposome Components
Effect
Ref.Reconstitution
(Protectant:lipids Ratio)
Avoiding Leakage
(Substance)
Trehalose
DPPC
EPC
DSPC:DSPE-PEG2000:ls-PG
POPC:DSPE-PEG2000:ls-PG
DPPC:DPPG:CHOL
DOTAP:DOPE
DOTAP:DOPE:DSPE-PEG
SPC or EPC:CHOL:DOTAP
HSPC:CHOL:DOTAP
DPPC:CHOL:DSPE-PEG
DOTAP:CHOL
EPC:CHOL
Y (> 0.5:1)
Y (> 0.3:1 w/w)
Ineffective (CF)
Ineffective (CF) [53]
Y (5-10:1 w/w)
Y (5-10:1 w/w)
-
- [23]
Y (5% w/w in; 15% out) Effective (doxorubicin) [48]
Y (57:1 w/w)
Y (51:1 w/w)
-
- [63]
Y (5-15:1 w/w)
Y (5-25:1 w/w) Effective (< 10:1 w/w) (ATP) [60]
Y (6:1 w/w) Ineffective (prednisolone) [65]
Y (1.6-3.7:1 w/w) Ineffective (decapeptide) [66]
Y (2-8:1 mol/mol)
N (10:1 mol/mol)
Effective at 4:1 mol:mol
(ibuprofen) [44]
Maltotriose DOPC or EPCDPPC
-
-
Ineffective (calcein)
Effective (calcein)
[60]
Maltotetraose DOPC or EPCDPPC
-
-
Ineffective (calcein)
Effective (calcein)
Maltoexaose DOPC or EPCDPPC
-
-
Ineffective (calcein)
Effective (calcein)
Maltoheptaose
DOPC or EPC
DPPC
-
-
Ineffective (calcein)
effective (calcein,>90%)
DPPC - Ineffective (calcein, 75%) [62]
HES EPC Y (0-500 mg/mL) Ineffective (CF) [61]
Dextran (1.5 kDa) DOTAP:DOPEDOTAP:DOPE:DSPE-PEG
Y (57:1 w/w)
Y (51:1 w/w)
-
-
[63]
Dextran (5 kDa) DOTAP:DOPE Y (57:1 w/w) -
Dextran (40 kDa) DOTAP:DOPE:DSPE-PEG Y (57:1 w/w) -
Dextran (480 KDa) DPPC or EPC Y (5-15:1 w/w) Ineffective (CF) [53]
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Table 2. Cont.
Protectant Liposome Components
Effect
Ref.Reconstitution
(Protectant:lipids Ratio)
Avoiding Leakage
(Substance)
Inulin (1.8 kDa) DOTAP:DOPEDOTAP:DOPE:DSPE-PEG
Y (57:1 w/w)
Y (51:1 w/w)
-
- [63]
Inulin (4 kDa) DOTAP:DOPEDOTAP:DOPE:DSPE-PEG
Y (57:1 w/w)
Y (51:1 w/w)
-
- [63]
HP-β-cyclodextrin DPPC:CHOL:DSPE-PEG Y (6:1 w/w) Effective (prednisolone) [65]
Quercetin-3-O-glucoside
EPC
EPC:EPE
EPC:DLPE
Y (30 mol %)
N (30 mol %)
Y (30 mol %)
Ineffective (CF) [42]
Quercetin-3-O-rhamnoside
EPC
EPC:EPE
EPC:DLPE
Y (30 mol %)
N (30 mol %)
Y (30 mol %)
Ineffective (CF) [42]
Kaempferol-3-O–glucoside EPC or EPC:EPE or EPC:DLPE Y (30 mol/mol) Ineffective (CF) [42]
Kaempferol-7-O–glucoside EPC or EPC:EPE or EPC:DLPE Y (30 mol/mol) Ineffective (CF) [42]
Arginine EPC:CHOL Y (4:1 mol/mol, only) Effective (ibuprofen) [44]
Histidine EPC:CHOL Y (4:1 mol/mol) Effective (ibuprofen) [44]
Lysine EPC:CHOL Y (2-4:1 mol/mol) Effective (4:1 mol:mol)(ibuprofen) [44]
Gelatin SPC:CHOL Y (5-20% w/v in) Effective (>10%, 94.2% CF) [67]
Abbreviations: POPC: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; DSPC: 1,2-distearoyl-sn-glycero-3-phosphocholine; ls-PG: 1-stearoyl-2-hydroxy-sn-glycero-3-[phospho-rac-1-
glycerol]; DSPE-PEG2000: 1,2-distearoyl-sn-glycero-3-Phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]; EPC: Egg yolk L-a-phosphatidylcholine; DOPC:
Dioleoyl-t-c~-phosphatidylcholine; DPPC: dipalmitoyl-L-ce-phosphatidylcholine; DPPG: 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol); CHOL: cholesterol; SPC: Soybean
phosphatidylcholine; SPS: soybean phosphatidylserine; DOTAP: N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium; DOPE: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; CF:
carboxyfluorescein; DLPE: 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine; EPE: egg phosphatidylethanolamine; HSPC: L-α-phosphatidylcholine, hydrogenated (Soy); in/out: in,
inside the liposome core; out, in the bulk medium. Y: Yes; N: No.
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It is well-accepted that water replacement and vitrification theories are not excluding each other,
but rather these mechanisms cooperate to protect liposomes during freeze-drying [7]. However,
they cannot completely explain the results reported in the literature. Indeed, it should be also
considered that the Tm of dispersions increases as the water activity decreases in the presence of
high concentrated solutes [68]. As an example, Strauss et al. found that the addition of up to
10% sucrose to hydrated multilamellar vesicles of DPPC elevated the Tm by several degrees [69].
Furthermore, the thermal behavior of the system is influenced by the type of vesicles and the extent of
protectant. In the case of large DPPC multilamellar liposomes, the addition of mono- and disaccharides
raised and broadened the Tm. The addition of high strengths of sucrose and trehalose to unilamellar
vesicles made of the same phospholipid created multiple metaphases [70]. Furthermore, it is generally
recognized that high quantities of sugars, that are required to guarantee a reproducible protective
effect, could influence the viscosity and, therefore, the rehydration of the vesicles [71]. In the definition
of the amount of protectant, its impact on the tonicity of the reconstituted solution has to be carefully
evaluated to avoid a negative effect on the safety of the drug product administered by ocular and
parenteral route. However, this aspect is not sufficiently discussed in the literature.
The use of more complex carbohydrates gave contrasting results. As an example, maltodextrins
are commonly used to preserve the main of nanomedicines upon lyophilization [72], since Tc increases
with the increase of glucoside units. In other words, in theory, maltodextrin or dextran would be more
convenient to be freeze-dried with respect to trehalose and sucrose (Table 3). However, increasing the
glucoside unit number the steric hindrance increases and number of H-bonds among the sugar and
the polar head decreases, limiting the stabilizing effect (Table 2) [62]. Similarly, hydroxyethyl starch,
although the high Tg that allows to prevent the vesicle fusion, had a poor stabilization effect [61].
In fact, it was not able to depress the Tm in the dehydrate state and, therefore, it could not prevent the
leakage of the entrapped drug upon rehydration of the liposomes (Table 2).
Instead, dextrans with a molecular weight up to 40 KDa avoided the aggregation of lipoplexes
after lyophilization [63]. Dextran at higher molecular weight (480 KDa) was able to stabilize DPPC
liposomes, but completely failed in the case of liposomes composed of unsaturated lipids having very
low Tm such as EPC (Table 2) [73]. In the last case, the lack of stabilizing effect was ascribed to the
fact that dextran was not able to depress the Tm and/or interact with polar heads, inhibiting by a
non-competitive mechanism also the effect of trehalose. Other polysaccharides have been also tested.
As an example, hydroxypropyl methylcellulose (HPMC) 4000 in combination with mannitol resulted
effective to preserve the main physico-chemical features of felodipine loaded liposomes intended for
cutaneous application [74].
Table 3. Collapse temperature (Tc), glass transition temperature of maximum freeze concentrate (Tg’)
and water content remaining within an amorphous phase (Wg’) of various solutes (adapted from [75]).
Compound Tc (◦C) Tg’ (◦C) Wg’ (%)
Glucose −40 −43 29.1
Fructose −48 −42 49.0
Sorbitol −27 −43 18.7
Inositol −27
Sucrose −32 −32.0 35.9
Lactose −32 −28.0 40.8
Maltose −32 −29.5 20.0
Raffinose −26 −26.5
Threalose −29.5 16.7
Dextran −9 −9
HPβCD (hydroxypropyl-β-cyclodextrin) −8 −8
Poly(vinyl pyrrolidone) −23 −19.5
Poly(ethylene glycol) −13 −13
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Liposomes to be given parenterally are generally functionalized with hydrophilic moieties, mainly
poly(ethylene glycol) (PEG) 2000, to reduce the opsonization phenomenon, or with targeting agents able
to drive the carrier to particular cells or tissue. Hyaluronan (HA) is one of the most studied targeting
agents, for example, in anticancer therapy [76]. Peer and coworkers suggested that the decoration
of liposomes with HA may also protect liposomes upon lyophilization [71]. As far as PEGylated
liposomes is concerned, it should be mentioned that the freeze-drying of these formulations has some
additional challenges [77]. In fact, owing to instrumental limitations, the process temperatures are
generally above the Tg’ of PEGs which range from −85 to −65.8 ◦C, depending on the molecular
weight [63]. The selection of protectants has to be carried out with the purpose to increase the Tc value
of the whole system and, at the same time, considering the compatibility of the selected excipient with
PEG [7]. As an example, dextrans with a molecular weight higher than 5 KDa were not compatible
with PEG causing liposome aggregation also at very low temperatures of storage (i.e., −20 ◦C) [63].
Instead, the cyclic oligosaccharide hydroxypropyl-β-cyclodextrin (HPβCD) allowed the reconstitution
of the formulations and resulted more effective in avoiding the drug leakage than trehalose and sucrose
probably due to the huge number of hydrogen donors and acceptors present in the molecule [65].
The protective effect of HPβCD was ascribed to interactions with the polar heads of phospholipids
that impact on the packing of the hydrophobic moieties. However, the presence of cholesterol and the
saturation of the phospholipid acyl chains significantly influenced the HPβCD performances [24].
Recently, Popova et al. proposed glycosides as novel excipients able to protect the lipid membrane.
With respect to the classic carbohydrates, flavonols are amphipatic compounds enable both to form
H-bonds with the polar heads of lipids and to intercalate in the liposome bilayer. The stabilizing effect,
however, resulted to be strictly dependent on the nature of flavonols (i.e., the extent of glycosylated
moieties) and on the composition of the vesicles. In particular, it was hypothesized that the presence
of non-bilayer lipids favored the localization of the flavonols on the bilayer surface, leading to the
stabilizing effect [78].
Beside sugars, other molecules with different protection mechanisms were investigated as
adjuvants for freeze-dried liposomes. They include also amino acids: proline, arginine, lysine and
histidine [44]. Amino acids, used with disaccharides, can stabilize the system not only with H-bonds,
but also with electrostatic interaction. For this purpose, lysine seems to have similar protective effects
to trehalose [44]. Moving the attention to proteins, the loading of gelatin inside the vesicles permitted
the formation of a gel during the cooling of the liposomal dispersion providing an inner mechanical
support [67] and preventing the drug leakage [79]. Later studies of the same research team highlighted
that by covering the external surface of liposomes with polymers (in this study calcium alginate),
their physical stability upon freeze-drying increased [80].
It should be mentioned that, even if protectants are essential to allow the reconstitution of
liposomal formulations, their Tg’ values are generally lower than Tc (Table 3) and, therefore, their use
in the definition of primary drying protocols leads to conservative cycle. In the same way in the
selection of a protectant, its Tc or Tg’ value should be taken into consideration since the lower the value
the shorter the freeze-drying cycle.
Use of Organic Solvent as Adjuvants
Organic solvents, usually tert-butyl alcohol (TBA), are widely used to increase the sublimation
rate (which allows to design shorter processes), the chemical stability of pre-dried bulk solution and
dried products [81].
In the attempt to increase the efficiency of the manufacturing process, the possibility of
freeze-drying already formed liposomes using a TBA/water co-solvent system was investigated.
Although TBA is not monographed in the United State Pharmacopeia (USP) or European Pharmacopeia
(EP), neither listed in the guideline on impurities issued by the International Council for Harmonisation
of Technical Requirements for Pharmaceuticals for Human Use (ICH), it is likely to fall in the category
of a class 2 solvent based on the similarity of acute DL50 toxicity data [82]. The addition of low
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concentration of TBA (<20%) results in the crystallization of bulk ice and eutectic A [83]. Moreover,
in the presence of TBA, needle-shape crystals were formed with a substantially larger surface area that
the spherical ice crystal formed when TBA was not present [84]. The higher specific area, the faster the
sublimation of solvents and, therefore, the shorter the primary drying stage. However, the eutectic
A crystals would cause extra injuries in liposomes, as in case of soybean phosphatidylcholine
liposomes [85] or a reduction of the entrapment efficiency after freeze-drying [86]. This tendency can
be counterbalanced by the presence of a protectant, such as sucrose, which can significantly inhibit
the crystallization of the eutectic A [85]. However, the addition of solutes characterized by a high Wg’
value can affect also the residual TBA in the dried product [87]. Indeed, solvents can be retained within
the freeze-dried cake after lyophilization. Two theories used to explain this phenomenon are “selective
diffusion” and “microregion entrapment”. It is postulated that the retention is not due to adsorption to
the dried material. The solvent retention appears to occur in localized micro-regions where the solvent
is initially frozen, and the exacerbation of secondary drying conditions do little decrease the residual
amount probably because of the formation of H-bonds to the dried product [81].
5. Quality by Design
To obtain a well-design freeze-drying process, the application of Quality by Design (QbD)
paradigm should be also applied based on the following aspects [88]:
1. definition of the target product quality profile,
2. determination of the critical quality attributes (CQAs) and critical process parameters (CPPs),
3. risk assessment,
4. development of an experimental design aiming to investigate the impact of CPPs on CQAs and
establish a design space
5. design and implementation of a control strategy to ensure a continuous improvement.
As an example, Sylvester et al. applied the QbD approach to improve the final product quality of
liposomes loaded by pravastatin in terms of drug leakage, size, ζ-potential, residual moisture contents,
Tg and cake appearance, and to shorten the freeze-drying process as much as possible [89]. Among the
CPPs influencing the CQAs (Figure 6), the impact of freezing rate, inclusion of an annealing step and
primary drying at temperatures below and above Tg’ or slightly higher Tc were investigated.
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The results indicated that the process delivers the desired quality of the product as long as
operates within the design space. Moreover, the generated model through the D-optimal experimental
design could be further used to select an optimal formulation out of the design space. Despite the
general knowledge on this topic, the optimal formulation containing both trehalose and mannitol was
frozen at 1 ◦C/min and annealed for 2 h at −25 ◦C; the primary drying was carried out at −20 ◦C
for about 22 h [89]. This approach can be obviously applied to the other critical factors affecting the
quality of lyophilized liposomal formulation, namely, the freezing temperature [90] and the selection
of protectant [91].
6. Quality Attributes of the Freeze-Dried Liposomes
Liposomes are intended to optimize pharmacokinetic and pharmacodynamic properties of the
loaded drug. Consequently, it is mandatory to identify the physical, chemical and biological properties
of a liposomal formulation that would influence the in vivo performances and to develop reliable
assays aimed to assure that the quality of the formulation is maintained after reconstitution of the
freeze-dried product. Thus, two sets of CQAs should be identified: the former defines criticism
of the lyophilized products, e.g., the residual moisture content and, when necessary, the cake
appearance and the reconstitution time; the latter is referred to the reconstituted, and eventually
diluted, liposome dispersion, which represents the final pharmaceutical dosage form (Figure 7).
The sterility of the product is an important attribute whenever parenteral, pulmonary or ocular
formulations are considered.
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content was <1% in freeze-dried doxorubicin-loaded liposomes no significant physical instability
or chemical degradation was observed over a 6-month period at temperature up to 30 ◦C [93].
Furthermore, the residual water content directly influences Tg of the protectants, which is related
to the stabilization of liposomes in the glass matrix [27,88]. Indeed, after freeze-drying amorphous
components remain vitrified only in case that the storage temperature (Ts) is well below Tg of the glass.
As a rule of thumb, a temperature difference “Tg − Ts” of, at least, 50 ◦C was proposed [93].
The traditional batch-wise lyophilization practice has some important drawbacks mainly due to
uncontrolled vial-to-vial and batch-to-batch end product variability. Hence the consistency of some
of the CQAs mentioned above cannot be easily achieved as lyophilization is a complex interplay of
dynamic and nonequilibrium processes. From a regulatory point of view, such uncontrolled variability,
which could lead to unexpected features of a medicinal product, is not desired. Thus, there is a
clear need to move in different directions from the enhancement of the process knowledge to the
extension of the extensive process control through the definition of techniques to monitor and control
the quality attributes of the freeze-dried product in a rapid and non-destructive way. Moreover,
the FDA Inspection technical guide on lyophilization of parenterals states that “the USP points out
that it is good pharmaceutical practice to perform 100% inspection of parenteral products. This includes
sterile lyophilized powders. Critical aspects would include the presence of correct volume of cake and the
cake appearance. With regard to cake appearance, one of the major concerns is meltback” [94]. Indeed,
the examination of the cake appearance is an important attribute of freeze-dried products since it can
be observed on the entire batch and harmonized nomenclature and description for variations in cake
appearance was recently proposed to overcome challenges related on how to judge the criticality of
cake appearance [51]. However, this attribute may or may not be critical with respect to product safety
and efficacy. Indeed, sometimes ”a non-ideal cake appearance”, namely not elegant and uniform, has
no impact on product quality and it is an inherent characteristic of the product due to formulation,
drug product presentation, and freeze-drying process. As an example, a remarkable influence of TBA
on final liposomal product was that the cake was friable. Manual shaking led to the formation of
free-flowing powder. This quality attribute of dried cakes may result from the modification of the ice
habit (i.e., needle-shape vs spherical ice-crystals) in the presence of TBA, but it did not impact on the
size distribution of liposome dispersions upon reconstitution [81].
Nevertheless, the cake appearance may be also related to changes in the microstructure of the
product and, in that case, this quality attribute has an important relevance. For this reason, the visual
inspection of the cake is not enough, but it has to be supported by imaging techniques such as scanning
electron microscopy (SEM) that allows to analyze the surface topography, roughness, and morphology
of solids at high resolution [95]. For example, as stated in the Section 4, the crystallization of the
protectant upon lyophilization can damage the liposome structure. This effect may be observed
by microscopic evaluation of freeze-dried cakes (Figure 4B). However, there are several criticisms
which limit the possibility to obtain quality images by this technique. First, unwanted changes in the
freeze-dried product can occur during sample preparation, e.g., during sputter coating and the vacuum
during the measurement. Furthermore, due to low optical contrast, the morphology of lyophilized
products is difficult to observe, and internal structures are normally not visible, unless the cake is
fractured. Because most lyophilized substances are hygroscopic and fragile, a brief contact with the
humidity in the atmosphere can alter the cake texture or the product can be damaged upon removal
of the from the vial. As an alternative, X-ray microcomputed tomography (µCT) was proposed to
provide a wide range of structural information on the surface and cross-sectional morphologies of the
scaffolds, including pore distribution, size, and interconnectivity [96,97].
NIR spectroscopy was investigated to offer real-time information on CQAs, such as water to ice
conversion, product crystallization, solid-state characterization and residual moisture determination.
As already mentioned, NIR spectroscopy was also used as a complementary in-line tool to determine
the drying end point in the attempt to optimize of freeze-dried liposomes [89]. However, the inherent
limitation of this method is that only a fraction of the vial can be monitored, and intra-vial variability
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is thus not taken into account [89]. More recently the use of near-infrared chemical imaging (NIR-CI)
was proposed for process monitoring because it combines the chemical information from the spectral
features in the NIR region with the spatial information on the constituent distribution derived from
the pixel-to-pixel spectral variation [98]. NIR-CI allows to discriminate among mannitol-sucrose
formulations lyophilized with different drying time, to reveal within-vial inhomogeneity in water
content and to characterize the solid-state of the entire lyophilized cake with a high spatial
resolution [98]. However, some practicalities are still to be overcome in view of a broader applicability.
Nowadays, the attention is also focused on the study of the compressive mechanical properties
of the freeze-dried cakes directly in glass vials by using a texture analyzer [99]. The optimized
experimental set-up evidenced that cakes formed by different excipients, namely mannitol, sucrose,
treahose [99], gelatin maltodextrin, and poly(vinyl pyrrolidone) (PVP) K40 [100] exhibited different
brittle cracking/crushing failure. Furthermore, this technique was sensitive to differences in freezing
conditions for sucrose formulations and the moisture content of sucrose cakes [99].
When unsaturated lipids are present in the formulation, the full degradation profile of lipids
should be carefully monitored in the liposomal cake, with particular attention on the formation of
lysolipids, which are the cause of toxic reactions, such as hemolysis and apoptosis. The lysolipid
content has to be controlled both during the production process and the shelf-life of the product [101].
The extent of lipid degradation or peroxidation should be monitored over a range of storage
temperatures because the phenomenon is temperature dependent and may increase increasing the
storage temperature [102].
6.2. Criticisms of The Reconstituted Liposomal Dispersion
The ability of the freeze-dried cake to readily reconstitute upon addition of an appropriate medium
is dependent on several factors. Undesired physical structure of the freeze-dried powder (e.g., degree
of cake collapses or meltback, the surface area of the cake and the inhomogeneity of the dried matrix)
can lead to poor wetting, dispersion and capillarity, agglomeration, unwanted particulate formation
during reconstitution, or prolonged reconstitution time. Currently, no procedures are available to
monitor the reconstitution of freeze-dried pharmaceutical formulations. Moreover, modalities of
reconstitution are also relevant for the generation of the desired average particle size distribution of
liposomes avoiding the formation of aggregates which may determine the incidence of undesired
reactions. The main findings reported in the literature on this topic are summarized in Table 2.
Destabilization of a reconstituted colloidal suspension can be evaluated by dynamic light
scattering (DLS) which is the most user-friendly technique, and it yields relatively accurate and
consistent results in a rather short period of time. Differences in size distribution, a polydispersity
index close to 1 and high coefficients of variation are indices of fusion and/aggregation. DLS is
also known to have several drawbacks, which are mainly inherent to the principles of the technique.
Particle size is determined from fluctuations in scattered light intensity due to the Brownian movement
of the particles. Since its measurement considers the intensity of light scattered by spherical particles,
this technique is not very sensitive for highly polydisperse and non-spherical colloidal systems [103].
FDA guideline indicates that nanoparticle tracking analysis (NTA) can be also used to evaluate size
distribution of a liposomal suspension both during research and routine quality controls. Considering
that NTA also provides quantitative information [104], the potentiality of this technique can be also
exploited to evaluate the concentration of liposomes in a known volume of reconstitution medium.
Along with the particle size, it is important to ensure that the morphology and/or structure of
the liposomes do not change after reconstitution. The lamellarity of liposomes in fact impacts on the
drug release kinetics, along with the stability of liposomes against protein once injected and, more
in general, on their in vivo performances. The structure of the liposome after reconstitution could
be examined by imaging analyses usually using transmission electron or cryoelectron microscopy.
Moreover, to obtain a deeper insight into the fine structure of the bilayer, SAXS or small angle neutron
scattering measurement could be adopted [39].
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Generally speaking, liposomal dispersion contains electrically charged particles whose
interactions can strongly affect physical stability, rheological behavior, sedimentation, re-dispersion,
and filtration. One of the most useful parameters to understand such interactions is the ζ-potential.
In particular, variations of this value in the reconstituted dispersion can be attributed to particle
aggregation, to the presence of an absorbed layer on the interface or also to the drug leakage, which is
the most well-known drawback of the freeze-drying process of liposomes, mainly when hydrophilic
cargoes, that do not interact with the bilayer, are considered. Drug leakage is mainly attributed to
vesicle fusion and/or gel to liquid–crystalline phase transitions of the membrane lipids during drying
with consequent loss of the encapsulated material. To control the drug leakage, liposomal cake is
generally washed and the unentrapped drug is removed from the reconstituted dispersion through a
proper purification method (e.g., column separation) prior of the assay of the drug still encapsulated
in the vesicles [105]. This is of course one of the first controls to be carried out after freeze-drying to
assure the loading of therapeutic dose.
7. Conclusion
After decades of studies in this field, no “rules of thumbs” can be proposed to make the design
and development of a freeze-dried liposomal formulation easier. Indeed, it is not just a matter of the
type and location (bulk water or vesicle inner core) of protectant or the definition of process parameters,
but it is the intricate relation among such variables and bilayer composition which determines the
success of lyophilization to stabilize liposomes in a dried state.
The current guidelines issued by the main regulatory agencies on the development of liposomal
products [9,106] do not mention any tools to characterize the quality of the freeze-dried products.
Nevertheless, since many efforts have been designed to develop dried liposomal dosage forms and
few products have been already tested by clinical trials [5,6], there is an urgent need to release
some specifics on the quality control of lyophilized liposomal products at the regulatory level.
Recent advances in imaging techniques combined with the information related to the reconstituted
suspensions could improve the know-how required not only to optimize the process, but also quality
controls of lyophilized formulations at an industrial level.
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